Hepatitis Vaccine Conferences | Europe | Global Events | USA | Middle East | Asia Pacific | 2016 | 2017

Theme:

Hepatitis vaccines 2016

Scientific Program (2016)

Hepatitis vaccines 2016

The liver is the largest gland in the human body. It weighs approximately 3 lb (1.36 kg). It is reddish brown in colour and is divided into four lobes of different sizes and lengths. It is also the largest internal organ (the largest organ is the skin). It is below the diaphragm on the right in the thoracic region of the abdomen. Blood reaches the liver through the hepatic artery and the portal vein. The portal vein carries blood containing digested food from the small intestine, while the hepatic artery carries oxygen-rich blood from the aorta. Most liver damage is caused by 3 hepatitis viruses, called hepatitis A, B and C. However, hepatitis can also be caused by alcohol and some other toxins and infections, as well as from our own autoimmune process (the body attacks itself)

About 250 million people globally are thought to be affected by hepatitis C, while 300 million people are thought to be carriers of hepatitis B. Not all forms of hepatitis are infectious. Alcohol, medicines, and chemical may be bad for the liver and cause inflammation. A person may have a genetic problem, a metabolic disorder, or an immune related injury.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. Conference series LLC proudly announces “International Conference on Hepatitis Vaccines and Liver Diseases” which will be held during October 24-25, 2016 in Valencia, Spain. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

10^th Euro Global Summit and Expo on Vaccines & Vaccination June 16-18, 2016 Rome, Italy; 11^th Global Summit and Expo on Vaccines, Vaccination and Therapeutics September 12-14, 2016 Phoenix, USA; 12^th Asia Pacific Global Summit and Expo on Vaccines & Vaccination November 24-26, 2016 Melbourne, Australia; International Conference on Travel Medicine, Vaccines & Therapeutics August 01-02, 2016 New Orleans, USA; World Congress on Children Vaccines October 10-12, 2016 Kuala Lumpur, Malaysia; 14^th Annual Congress on Influenza Respiratory Diseases & Infections : Vaccines and Therapeutics; 15^th Annual Conference on HIV Vaccines & Therapeutics December 8-9, 2016 Philadelphia, USA; 10^th ISV Annual Vaccine congress 02-04 Oct 2016 Boston, USA; World Vaccines Congress Asia 03-04 June 2016 Singapore; Annual Pennsylvania Immunization Conference 16 June 2016 Pennsylvania; Immunization Summit 21-22 June 2016 Charleston; 10th Vaccine Congress 04-07 Sep Netherlands.

Track 2: Transmission of Hepatitis

Hepatitis B is found in blood and in body fluids, including semen and vaginal fluids. Even though studies have shown minute quantities of the virus can be present in saliva, tears and breast milk, they are not considered to be in high enough levels to transmit the virus.

The most common ways hepatitis B is spread include:

Ø sexual contact

Ø sharing of injecting equipment

Ø needlestick injuries in a health care setting

Ø reuse of unsterilised or inadequately sterilised needles

Ø child-to-child transmission through household contact such as biting

Ø sharing personal items such as razors, toothbrushes, or hair and nail clippers

Ø mother-to-baby, though it is to be noted that the Australian vaccination program has significantly reduced this risk through the administration of the vaccine within 12 hours of birth.

Hepatitis B is NOT spread by contaminated food or water, and cannot be spread through casual or social contact such as kissing, sneezing or coughing, hugging, or eating food prepared by a person with hepatitis B.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 3: Autoimmune Hepatitis

Autoimmune hepatitis is liver inflammation that occurs when your body's immune system turns against liver cells. The exact cause of autoimmune hepatitis is unclear, but genetic and environmental factors appear to interact over time in triggering the disease. Untreated autoimmune hepatitis can lead to scarring of the liver (cirrhosis) and eventually to liver failure. When diagnosed and treated early, however, autoimmune hepatitis often can be controlled with drugs that suppress the immune system. A liver transplant may be an option when autoimmune hepatitis doesn't respond to drug treatments or when liver disease is advanced.

Causes : Autoimmune hepatitis occurs when the body's immune system, which ordinarily attacks viruses, bacteria and other pathogens, instead targets the liver. This attack on your liver can lead to chronic inflammation and serious damage to liver cells. Just why the body turns against itself is unclear, but researchers think autoimmune hepatitis could be caused by the interaction of genes controlling immune-system function and exposure to particular viruses or drugs.

Types of autoimmune hepatitis :

Type 1 autoimmune hepatitis. This is the most common type of the disease. It can occur at any age. About half the people with type 1 autoimmune hepatitis have other autoimmune disorders, such as celiac disease, rheumatoid arthritis or ulcerative colitis.

Type 2 autoimmune hepatitis. Although adults can develop type 2 autoimmune hepatitis, it's most common in children and young people. Other autoimmune diseases may also accompany this type of autoimmune hepatitis.

Treatment for autoimmune hepatitis includes medication to suppress, or slow down, an overactive immune system. Treatment may also include a liver transplant. Treatment works best when autoimmune hepatitis is diagnosed early. People with autoimmune hepatitis generally respond to standard treatment and the disease can be controlled in most cases. Long-term response to treatment can stop the disease from getting worse and may even reverse some damage to the liver.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 4: Acute Hepatitis

The course of illness resembles acute viral hepatitis with insidious onset, a hepatocellular pattern of injury and jaundice. Symptoms (if present) include fatigue, anorexia, nausea and right upper quadrant tenderness. Illness typically lasts 2 to 4 weeks and ultimately resolves, but severe instances can result in acute liver failure and death. The time to onset of acute hepatitis is typically 2 to 24 weeks; unlikely after 52 weeks or before 4 days.

Typical agents that cause an acute viral hepatitis like illness include isoniazid, pyrazinamide, disulfiram, fenofibrate, ephedra, greater celandine, green tea, and other herbals. People with hepatitis should not drink alcohol until they have fully recovered. A doctor may need to stop a drug or reduce the dosage of a drug that could accumulate to harmful levels in the body (such as warfarin or theophylline) because the infected liver cannot process (metabolize) them. Thus, people should tell their doctor all the drugs they are taking (both prescription and nonprescription, including any medicinal herbs), so that the dosage can be adjusted if necessary.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 5: Viral Hepatitis

Hepatitis means inflammation of the liver. hepatitis is ofenly caused by a liver. Viruses that primarily attack the liver are called hepatitis viruses. There are several types of hepatitis viruses including types A, B, C, D, E, and possibly G. Types A, B, and C are the most common. All hepatitis viruses can cause acute hepatitis. Viral hepatitis types B and C can cause chronic hepatitis. The symptoms of chronic viral hepatitis often are mild and nonspecific, and the diagnosis of chronic hepatitis often is delayed. Although the most common types of viral hepatitis are HAV, HBV and HCV, some clinicians had previously considered the acute and chronic phases of hepatic infections as "types" of viral hepatitis. HAV was considered to be acute viral hepatitis because the HAV infections seldom caused or permanent liver damage that led to hepatic (liver) failure. HBV and HCV produced chronic viral hepatitis. However, these terms are outdated and not currently used as frequently because all of the viruses that cause hepatitis may have acute phase symptoms.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 6: Advances In Hepatitis Testing

The incidence of Hepatitis C is rising in this country. Recently, the United States Centers for Disease Control (CDC) issued a recommendation that “baby boomers,” anyone born between 1945 and 1965, be tested for HEP C. According to the CDC over 3.5 million Americans are HEP C positive and most unaware that they have this disease. Consequently the testing, treatment and care provided by SCC is more important than ever. However, not only “baby boomers” should be tested but past and present IV drug users and those with HIV/AIDS are at risk as well. Chronic HEP C has various symptoms, but sometimes none at all, and is highly damaging to the liver. At SCC, we offer a rapid HEP C with results in 20 minutes. Should you test positive, the most up-to-date medical care and advanced research options are available for your treatment and care.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 7: Hepatitis Vaccine

The best way to prevent hepatitis A is through vaccination with the hepatitis A vaccine. Vaccination is recommended for all children age 12 months and older, for travelers to certain countries, and for people at high risk for infection with the virus. The hepatitis A vaccine is given as two shots, six months apart. The hepatitis A vaccine also comes in a combination form, containing both hepatitis A and B vaccine, that can be given to persons 18 years of age and older. This form is given as three shots, over a period of six months or as three shots over one month and a booster shot at 12 months

· For children: The first dose should be given at 12-23 months of age. Children who are not vaccinated by two years of age can be vaccinated at later visits.

· For Travellers :Hepatitis A vaccine is recommended for healthy international travelers age 12 months or older; the first dose of Hepatitis A vaccine should be administered as soon as travel is considered. A shot called immune globulin (IG) can be considered in addition to hepatitis A vaccine for older adults, immunocompromised persons, and persons with chronic liver disease or other chronic medical conditions who are traveling within two weeks.

For Others:

· Men who have sexual contact with other men

· Users of certain illegal drugs, both injection and non-injection

· Family and caregivers before arrival of international adoptees

· People with chronic (lifelong) liver diseases.

· People who are treated with clotting-factor concentrates

· People who work with hepatitis A infected animals or in a hepatitis A research laboratory

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 8: Hepatitis B Vaccines

The best way to prevent hepatitis B is by getting the hepatitis B vaccine. The hepatitis B vaccine is safe and effective and is usually given as 3-4 shots over a 6-month period. Hepatitis B vaccination is recommended for:

Ø All infants, starting with the first dose of hepatitis B vaccine at birth

Ø All children and adolescents younger than 19 years of age who have not been vaccinated

Ø People whose sex partners have hepatitis B

Ø Sexually active persons who are not in a long-term, mutually monogamous relationship

Ø Persons seeking evaluation or treatment for a sexually transmitted disease

Ø Men who have sexual contact with other men

Ø People who share needles, syringes, or other drug-injection equipment

Ø People who have close household contact with someone infected with the hepatitis B virus

Ø Health care and public safety workers at risk for exposure to blood or blood-contaminated body fluids on the job

Ø People with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients

Ø Residents and staff of facilities for developmentally disabled persons

Ø Travelers to regions with moderate or high rates of hepatitis B

Ø People with chronic liver disease

Ø People with HIV infection

Ø People with diabetes 19 through 59 years of age, and considered for people with diabetes 60 years or older

Ø Anyone who wishes to be protected from hepatitis B virus infection

For Children And Adolescents :

All children should get their first dose of hepatitis B vaccine at birth and complete the vaccine series by 6–18 months of age. Hepatitis B vaccine is recommended for all babies so that they will be protected from a serious but preventable disease. Babies and young children are at much greater risk for developing a chronic infection if infected, but the vaccine can prevent this.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 9: Hepatitis C Vaccines

Acute Hepatitis C virus infection is a short-term illness that occurs within the first 6 months after someone is exposed to the Hepatitis C virus. For most people, acute infection leads to chronic infection.

Chronic Hepatitis C virus infection is a long-term illness that occurs when the Hepatitis C virus remains in a person’s body. Hepatitis C virus infection can last a lifetime and lead to serious liver problems, including cirrhosis (scarring of the liver) or liver cancer.

Hepatitis C is usually spread when blood from a person infected with the Hepatitis C virus enters the body of someone who is not infected. Today, most people become infected with the Hepatitis C virus by sharing needles or other equipment to inject drugs. Hepatitis C is rarely passed from a pregnant woman to her baby. About 6 of every 100 infants born to mothers with Hepatitis C become infected with the virus. However, the risk becomes greater if the mother has both HIV infection and Hepatitis C. acute hepatitis C & chronic Hepatitis C can be treated. Acute infection can clear on its own without treatment in about 25% of people. If acute hepatitis C is diagnosed, treatment does reduce the risk that acute hepatitis C will become a chronic infection. Vaccines are available only for Hepatitis A and Hepatitis B. Research into the development of a vaccine is under way.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 10: Hepatitis

Hepatitis refers to an inflammatory condition of the liver. It’s commonly caused by a viral infection, but there are other possible causes of hepatitis. These include autoimmune hepatitis and hepatitis that occurs as a secondary result of medications, drugs, toxins, and alcohol. Autoimmune hepatitis is a disease that occurs when your body makes antibodies against your liver tissue. Viral infections of the liver that are classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is a milder version of the disease, and hepatitis C and D are more severe. Treatment options vary depending on what form of hepatitis you have and what caused the infection. You can prevent some forms of hepatitis through immunizations or lifestyle precautions.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 11: Hepatitis Vaccines Market Analysis

Vaccines The World Market examines the market for vaccines used in humans to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines for diseases that are not currently vaccine-preventable. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2013 to 2017 period and forecasts are provided through 2022. The global market for human vaccines experienced strong growth through 2015. Through 2022, growth will be fueled by continued new product introductions, indication expansions for some products and rising usage, particularly in South America, Europe, India and China.

Sales Growth of Vaccines vs. Pharmaceuticals, 2013-2022, The World Vaccines Market by Vaccine Type, 2013-2022 (Pediatric: Combinations, Hepatitis, HIB, MMR , Poliovirus, , Others; Adult: Cervical Cancer, Hepatitis, Travel - DT - Misc., Total). The World Vaccines Market by Region, 2013-2022 (U.S., North America / Caribbean, South America, Europe, Japan, India, China, ROW, Total)

One of the major factors driving the global hepatitis B vaccines market includes increasing number of hepatitis B infection cases. In addition, increasing awareness about the treatment of disease and government initiatives are driving the global hepatitis B vaccines market. However, some of the factors such as high cost and non-willingness by people for any kind of vaccination are restraining the global hepatitis B vaccines market. Growing demographics and economies in the developing countries such as India and China are expected to offer good opportunities for global hepatitis B vaccines market. In addition, growing awareness and innovation of some new type of medications with better efficiency are expected to offer good opportunity for global hepatitis B vaccines market. Inadequate coverage of vaccines is one of the major challenges faced by global pediatric interventional cardiology devices market. Some of the latest trends that have been observed in global hepatitis B vaccines market include companies involved in mergers and acquisitions. In addition, it has been observed that companies are involved in R&D and product launches of more efficient products. Some of the major companies involved in global hepatitis B vaccines market are Merck, GlaxoSmithKline, Sanofi Pasteur and Human Biologicals Institute, a division of Indian Immunologicals Limited. Some other companies dealing having significant presence in the global hepatitis B vaccines market are Dynavax Technologies, LG Life Sciences, Janssen Pharmaceuticals and Kaketsuke.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 12: Hepatitis Vaccines Current Updates

The hepatitis A vaccine is given as two shots, six months apart. The hepatitis A vaccine also comes in a combination form, containing both hepatitis A and B vaccine, that can be given to persons 18 years of age and older. This form is given as three shots, over a period of six months or as three shots over one month and a booster shot at 12 months.

For Children: The first dose should be given at 12-23 months of age. Children who are not vaccinated by two years of age can be vaccinated at later visits.

For Travelers: Hepatitis A vaccine is recommended for healthy international travelers age 12 months or older; the first dose of Hepatitis A vaccine should be administered as soon as travel is considered. A shot called immune globulin (IG) can be considered in addition to hepatitis A vaccine for older adults, immunocompromised persons, and persons with chronic liver disease or other chronic medical conditions who are traveling within two weeks. IG without hepatitis A vaccine can be given to travellers who are younger than 12 months of age, allergic to a vaccine component, or who elect not to receive vaccine.

For Others: The hepatitis A vaccine series may be started whenever a person is at risk of infection:

Ø Men who have sexual contact with other men

Ø Users of certain illegal drugs, both injection and non-injection

Ø Family and caregivers before arrival of international adoptees

Ø People with chronic (lifelong) liver diseases.

Ø People who are treated with clotting-factor concentrates

Ø People who work with hepatitis A infected animals or in a hepatitis A research laboratory

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 13: Hepatitis Immunology & Vaccine Biology

Hepatitis B is a serious disease caused by a virus that attacks the liver. The virus, which is called hepatitis B virus (HBV), can cause lifelong infection, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death. Hepatitis B vaccine is available for all age groups to prevent HBV infection.

The currently used hepatitis B vaccines are made synthetically (i.e. they do not contain blood products) and have been available in the U.S. since 1986. You cannot get hepatitis B from the vaccine. Learn more.

This safe and effective vaccine is recommended for all infants at birth and for children up to 18 years. Adults, especially those who fall into a high-risk group, should also seriously consider getting the hepatitis B vaccine.

For Children and Adolescents:

All children and adolescents younger than 19 years of age who have not yet gotten the vaccine should also be vaccinated. "Catch-up" vaccination is recommended for children and adolescents who were never vaccinated or who did not get the entire vaccine series.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 14: Vaccine Recomdations-Dosages and Scheduling

Hepatitis C is a contagious liver disease that ranges in severity from a mild illness lasting a few weeks to a serious, lifelong illness that attacks the liver. It results from infection with the Hepatitis C virus (HCV), which is spread primarily through contact with the blood of an infected person. Hepatitis C can be either “acute” or “chronic.” The virus persists in the liver in about 85% of those infected. This chronic infection can be treated with medication: the standard therapy is a combination of peg interferon and ribavirin, with either boceprevir or telaprevir added in some cases. Overall, 50–80% of people treated are cured. Those who develop cirrhosis or liver cancer may require a liver transplant.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 15: Multiple Vaccines and Immune System Challenges

Hepatitis is also classed as a sexually transmitted disease (STD) because it can be passed on sexually, particularly during activities such as anilingus (rimming). The washing of genital and anal areas before sex, and the use of condoms or dental dams can help to prevent this risk. People contract STDs through sexual contact with an infected person. Some STDs have other, nonsexual means of transmission. Risk of contracting STDs can be reduced by avoiding sexual contact or by consistent use of condoms during sexual activity or by practicing safer forms of sexual intimacy. In some cases, people can further reduce their risk for contracting a sexually transmitted disease by being vaccinated.

When symptoms do appear they are similar to those of hepatitis A and may include:

Ø A short, mild, flu-like illness

Ø nausea, vomiting and diarrhoea

Ø loss of appetite

Ø weight loss

Ø jaundice (yellow skin and whites of eyes, darker yellow urine and pale faeces)

Ø Itchy skin.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 16: Pregnant and New Born Vaccination

A hepatitis C vaccine, a vaccine capable of protecting against hepatitis C, is not available. Although vaccines exist for hepatitis A and hepatitis B, development of a hepatitis C vaccine has presented challenges. No vaccine is currently available, but several vaccines are currently under development. The ability of the body to make protective antibodies after infection with hepatitis A led researchers to develop vaccines against the disease. Hepatitis A vaccine is made of killed hepatitis A viruses and causes the body's immune system to produce antibodies against the hepatitis A virus.

The first hepatitis B vaccine became commercially available in the United States in 1982. In 1986, a hepatitis B vaccine produced by recombinant DNA technology was licensed and a second recombinant-type hepatitis B vaccine was licensed in 1989. Babies normally get 3 doses of hepatitis B vaccine: 1st Dose: Birth 2nd Dose: 1-2 months of age 3rd Dose: 6-18 months of age Some babies might get 4 doses, for example, if a combination vaccine containing hepatitis B is used.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 17: Pre & Post Immunization Measures

Despite the challenges in studying hepatitis, considerable progress has been in made in characterizing Anti-Hepatitis immune responses. It has been estimated that approximately 20% of individuals are able to clear the infection spontaneously following acute Hepatitis infection, whereas the rest progresses to chronicity. Longitudinal studies of the two cohorts of patients during and after acute infection have defined immunologic correlates that are associated with viral clearance.

A strong T-Cell response, characterized by the production of effector cytokines including IFN-γ, and broad epitope specifically correlate with the resolution of acute infection. After clearance of the acute infection, memory T cells are maintained, but whether they can provide protection against reinfection is incompletely understood. While usually not resulting in sterilizing immunity, that is, prevention of acute infection after re-exposure especially to antigenically more divergent hepatitis strains, adaptive immunity protects against progression to chronic infection following repeated hepatitis exposure. As chronic infection persists, the number of epitopes recognized decreases and T-Cell responses are often lost. Since hepatitis-associated morbidity and mortality are caused by chronic infection, a vaccine, even if it only prevents viral persistence, would greatly ameliorate the problem. Although neutralizing antibodies are present during the chronic phase of infection, these antibodies are not able to clear the virus. Several mechanisms of viral escape from antibody-mediated neutralization have been postulated and tested. Recently, several human monoclonal antibodies against hepatitis envelope protein E1 or E2, which show cross neutralizing capability, were identified. These antibodies were able to prevent infection of heterologous hepatitis in the hepatitis pseudo particle and hepatitis cell culture model system, suggesting passive prophylaxis with exogenous neutralizing antibodies or eliciting high-affinity antibodies with similar specificity representing a viable strategy to prevent or more efficiently control hepatitis infections.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 18: Hepatitis Vaccines Trails

For the purposes of registration, a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

The first clinical trial of a hepatitis C vaccine in humans has demonstrated safety and unprecedented immune responses, according to research published this week in Science Translational Medicine. B-cells produce antibodies that go after specific invaders. With the hepatitis C virus constantly changing (much like HIV) and having multiple genotypes, it is challenging for scientists to get B-cells to work effectively in a hepatitis C vaccine.

Using “helper” T-cells instead of B-cells that target specific intruders, the new vaccine provokes the immune system to go after the virus with its own defenses. About 15 to 25 percent of people who become infected with hepatitis C clear the virus spontaneously, according to the U.S. Centers for Disease Control and Prevention (CDC). Researchers have known that a powerful T-Cell response plays a role in the body’s ability to do so.

The researchers used chimpanzee viruses as vaccine vectors in the trial. “The size and breadth of the immune responses seen in the healthy volunteers are unprecedented in magnitude for a hepatitis C vaccine,” lead researcher Ellie Barnes, of the Nuffield Department of Medicine at Oxford University, said in a press statement.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 19: Vaccine Recomdations for Immuno-Compromised

Anyone planning to travel abroad may need immunizations before departure. Although few immunizations are compulsory for international travel, some are recommended for the traveller’s protection. Some vaccines must be given in 2–3 doses several weeks apart. Therefore, a doctor should be consulted at least 2–3 months before departure. Children under 1 year, and people with a compromised immune system or serious underlying disorder may not be able to have some vaccinations, such as those for yellow fever and tuberculosis. Recommended vaccines are travel vaccinations that can protect you in areas where there is an intermediate or high risk for contracting certain illnesses. They also help prevent the spread of diseases from one country to another.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 20: Production Storage and Handling of Vaccines

That investigation forecasts the overall hepatitis therapies market will multiply in revenues from 2014 to 2025. That pharmaceutical segment is evolving. Newly approved medications are achieving commercial success and some products blockbuster status. Visiongain believes the strength of the hepatitis drugs market is its oral antiviral treatments enabling shorter treatment regimens and higher cure rates, reportedly with fewer side effects than the standard care – peg interferon and ribavirin. Sales expansion of the market will be stimulated by the approval and continued development of interferon- and ribavirin-free regimens as well as increased screening. The potential for the hepatitis therapies market is vast and budgetary cuts and regulatory hurdles will not derail its progress.

In 2014, the greatest interest in the hepatitis C market is the development of protease and polymerase antivirals. Several companies have molecules in phase II and III trials, with at least five expected to gain approval within the first half of our forecast period. The overall world hepatitis C drug market was worth $4bn in 2013, and we expect it to multiply in annual revenue by 2025. There exists promising R&D for those medicines, with high sales potential from this decade onwards. That market is rapidly developing and will contribute high revenues to the pharmaceuticals industry from 2015 to 2025.”

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 21: Hepatitis Vaccination in Daibetes and Chronic Illnesss

Epidemiology is the science that studies the patterns, causes, and effects of health and disease conditions in defined populations. It is the cornerstone of public health, and shapes policy decisions and evidence-based practice by identifying risk factors for disease and targets for preventive healthcare.

Hepatitis B virus (HBV) infection is a global public health problem. It is estimated that there are 240 million HBV carriers in the world, of who roughly 600,000 die annually from HBV-related liver disease. The implementation of effective vaccination programs in many countries has resulted in a significant decrease in the incidence of acute hepatitis B. Nevertheless, hepatitis B remains an important cause of morbidity and mortality.

The spectrum of clinical manifestations of HBV infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical or anicteric hepatitis to icteric hepatitis and, in some cases, fulminant hepatitis. During the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Extra hepatic manifestations also can occur with both acute and chronic infection.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 22: Vaccine Evalution & Clinical Trails

The future is bright for people with chronic hepatitis B, thanks in a large part to advancements in medical science. All drugs must go through a testing process, which involves three phases of clinical trials, to evaluate its safety and effectiveness before being approved. Vaccines are developed, tested, and regulated in a very similar manner to other drugs. In general, vaccines are even more thoroughly tested than non-vaccine drugs because the number of human subjects in vaccine clinical trials is usually greater.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track: 23 Vaccine Safety and Efficacy- Contraindications and Precautions

Vaccination is among the most significant public health success stories of all time. However, like any pharmaceutical product, no vaccine is completely safe or completely effective. While almost all known vaccine adverse events are minor and self-limited, some vaccines have been associated with very rare but serious health effects. Today, vaccine-preventable diseases are at or near record lows. Many people no longer see reminders of the severity and potential life-threatening complications of these diseases. Recent outbreaks of vaccine–preventable diseases show that even vaccinated people are at risk for disease if there is not adequate vaccine coverage in the population.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 24: Regulatory & Ethical issues in Vaccine development

Vaccines are responsible for many global public health successes, such as the eradication of hepatitis and significant reductions in other serious infections like polio and measles. Even so, vaccinations have also long been the subject of various ethical controversies. The key ethical debates related to vaccine regulation, development, and use generally revolve around (1) mandates, (2) research and testing, (3) informed consent, and (4) access disparities. Many vaccine-related ethical debates center on the evidence that access to vaccination depends to some extent on socioeconomic and racial ethnic minority status. Implicit in these discussions is the question of whether or not all lives are of equal value, and equally deserving of opportunities to be protected by vaccination.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 25: Current Challenges in Vaccine R & D

Vaccine development has played a hugely important role in combating infectious disease. New Vaccine techniques like in vitro gene-manipulation have opened up new approaches to vaccine development. This has rapidly grown into an exciting area of Vaccines against infectious diseases research in both academic and industrial laboratories. There are a number of scientific challenges which require multidisciplinary teams to solve problems in developing new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Recombinant-DNA techniques are invaluable as tools of analysis and antigen production. The surface of micro-organisms can also be minutely explored with the use of synthetic peptides and monoclonal antibodies. Nevertheless, these new technologies do not allow us to circumvent the need for detailed understanding of pathogens and the disease process. A lot of researches are going on improving/developing new vaccines and administration of vaccines.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 26: Acute Liver Failure

Acute liver failure is an uncommon condition in which rapid deterioration of liver function results in coagulopathy, usually with an international normalized ratio (INR) of greater than 1.5, and alteration in the mental status (encephalopathy) of a previously healthy individual. Acute liver failure often affects young people and carries a very high mortality. Acute liver failure, also known as fulminant hepatic failure, can cause serious complications, including excessive bleeding and increasing pressure in the brain. It's a medical emergency that requires hospitalization. Depending on the cause, acute liver failure can sometimes be reversed with treatment. In many situations, though, a liver transplant may be the only cure.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

Track 27: Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. The cell(s) of origin are believed to be the hepatic stem cells, although this remains the subject of investigation. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. The incidence of HCC is highest in Asia, Africa and Europe. where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of HCC.

Management of hepatocellular carcinoma (HCC) is best performed in a multidisciplinary setting. Patients should be cooperatively managed by hepatologists, transplant and hepatobiliary surgeons, medical oncologists, interventional radiologists, and palliative care specialists. Specifically, this is crucial to ensure that patients who are candidates for liver transplantation are referred in a timely manner. Major efforts are also needed to specifically warn patients with chronic liver disease to discontinue alcohol abuse.

Related Conferences Vaccines Conferences | Vaccinologists Meetings | ConferenceSeries Ltd :

ConferenceSeries Ltd invites all the participants from all over the world to attend "International Conference on Hepatitis Vaccines and Liver Diseases"during Oct 24-25, 2016 in Valencia, Spain which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Following the great success of the 9^th Global Summit and Expo on Vaccines & Vaccination, held during November 30-December 02, 2015 in San Francisco, USA, Conference series LLC is organizing the International Conference on Hepatitis Vaccines which is going to be held in Valencia, Spain in 2016. This will be the latest in the Conference series LLC annual Hepatitis vaccine meeting series with 500+ Attendees, to provide a forum where key vaccine stakeholders including academic researchers, public health clinicians, veterinarians, vaccine policy makers, and manufacturers can exchange ideas and collaborate. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Immunome Research. ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With members from around the world focused on learning about Vaccinology/Immunology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Immunology/Vaccinology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new vaccines developments, and receive name recognition at this event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Immunology/Vaccinology are hallmarks of this conference.

Target Audience:

Vaccinology/Immunology Students, Scientists
Vaccinology/Immunology Researchers
Vaccinology/Immunology Faculty
Medical, Pharmacy, Biotechnology Colleges
Vaccinology/Immunology Associations and Societies
Business Entrepreneurs
Training Institutes
Software developing companies
Manufacturing Medical Devices Companies
Data Management Companies
Machinery Manufacturing Companies

The International Conference on Hepatitis Vaccines and Liver diseases to be held at Valencia, Spain during October 24-25, 2016 hosted by ConferenceSeries Ltd through the theme “Current Trends & Innovations in Hepatitis Vaccine research", conference will explore the advances in Hepatitis Vaccines and vaccination. This conference could be an exceptional event that brings along a novel and International mixture of giant and medium cognizance on vaccines and vaccination, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world. ConferenceSeries Ltd Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members and Organizes 300+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies

Vaccination is a key to eradicate the diseases. It is a subject for the professionals who looks beyond the clinical prospects. Hepatitis vaccines 2016 amass all the extroverts under one roof of current advances.

For more details please visit- http://hepatitisvaccines.conferenceseries.com/

Vaccinology is a major field in eradication of diseases. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases. This chapter provides a brief overview of some of the main concepts of immunology and Vaccinology as they relate to immunization.

Why Valencia?

In 2015 there are 12 vaccines and related conferences are held in Spain. From that three are from Melbourne.

Melbourne City Council provides a free immunisation service for children to help protect them against childhood diseases such as measles, whooping cough, polio and tetanus. Providing a free immunisation service is another way Council delivers towards the Melbourne Vision. Around 22 Biological giants are working in Spain. Around 15 top universities are working on vaccines research in Spain.

Conference Highlights:

Hepatitis A Vaccines
Hepatitis B Vaccines
Hepatitis C Vaccines
STD-Hepatitis
Hepatitis Immunization
Hepatitis Vaccines Research
Hepatitis Vaccines Trials
Epidemiology
Travel vaccines
Business- Hepatitis Immune products

Why to attend???

Hepatitis vaccines 2016 could be an event that brings along a novel and International mixture of giant and medium Vaccinology innovation and incipient trends in vaccines and vaccination, leading universities and Vaccinology, vaccination research analysis establishments creating the conference an ideal platform to share expertise, foster collaborations across trade and world, and assess rising technologies across the world. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Vaccinology research are hallmarks of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event: vaccines@conferenceseries.net

Major Vaccines Associations in & around Melbourne.

· Vaccine research Association

· Spainn vaccination association

· Spainn medical association

· Spainn veterinary association

· Association of veterinary vaccination

Major Vaccines Associations Globally

· The International Society for Interferon and Cytokine Research

· The International Society of Neuroimmunology

· The International Union of Immunological Societies

· The Society for Mucosal Immunology

· The Society for Leukocyte Biology

· Transplantation Society

· British Society for Immunology

· Cell Death Society

· European Federation of Immunological Societies

· European Society of Gene Therapy

· Federation of African Immunological Societies

· Federation of American Societies for Experimental Biology

· Federation of Clinical Immunology Societies

· Immune Deficiency Foundation

· Infectious Diseases Society of America

Target Audience:

Hepatitis vaccines 2016 Targets, CEO’s , Directors, Scientists, Professors, Students of all Biotech & Pharma companies, Universities and colleges globally

Vaccines sales in global leader companies 2012(1^st quarter):

· Pfizer 2.2 B $

· Sanofi 1.7 B $

· Merck & Co 1.8 B $

· GSK 2.5 B $

· Novartis 0.44 B $

· EBS 0.88 B $

Companies Associated with Vaccines

· CareDx

· Atara

· Biotherapeutics

· Benitec Limited

· InterMune

· Biotron Limited

· BioDiem

· Antisense Therapeutics Limited

· GlaxoSmithKline Spain Pty Ltd

· Bionomics

· Spainn Pharmaceutical Industries (API)

· BioPharmica Limited

Market Analysis of Vaccines

Tripled in value from USD 5B in 2000 to almost USD 24 B in 2013, Global market projected to rise to USD 100 B by 2025. More than 120 new products in the development pipeline. 60 are of importance for developing countries. UNICEF had a market of 1,03 B$ in 2011, PAHO had 400 million dollars in 2011 and total UN market of 340 million dollars in 2002, 1,430 billion dollars in 2011.

Overall Statasticks

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 24-25, 2016
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2
Poster Opportunity Closed	Click Here to View

International Conference on Hepatitis Vaccines and Liver Diseases October 24-25, 2016 Valencia, Spain

Recommended Global Vaccines Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Hepatitis vaccines 2016

For Children And Adolescents :

Conference Highlights

To Collaborate Scientific Professionals around the World

Media Partners

Useful Links

Special Issues